12.06.19
5 min. Read

Sanofi’s in-house DTx. 1,162 clinical trials used digital tools in 2018.

Issue 030.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 62 percent open rate. Here's what's happening this week:

  • My backyard now features both a seven-foot-tall snowman and his companion snowdog, following the Greater Boston area's first snowstorm of the season.
  • Foley's telemedicine report focused on commercial payer laws throughout the US is well worth a read.
  • Nothing new but... in his first interview since assuming the post in July, when asked what changes he's made so far, Sandoz's top exec Richard Saynor told a German newspaper: "We decided to quit the business with so-called digital therapeutics (for example, apps that help addicts, ed.). While this is a fascinating area, it does not really suit the commercialization of generics." (translated from German) via FiercePharma
  • Swedish specialty pharmaco Orexo has

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
Better Therapeutics shuts down. Mahana-Cara Care
3.18.24
5 min. Read
HCPCS and CPT decisions. Akili results. Click trials
3.08.24
7 min. Read
De Novo: Samsung Galaxy Watch gets OTC sleep apnea detection
2.16.24
7 min. Read
Facebook’s RCT for AI bot Zenny. More trials
1.30.24
7 min. Read
FDA de novo for Google smartphone thermometer.
1.05.24
6 min. Read
PDT-to-virtual-clinic trend continues. HCPCS tweaks.
12.15.23
8 min. Read
Mahana Tinnitus. New CPT hopefuls. Better cuts salaries
12.01.23
6 min. Read
CMS weighs HCPCS for Natural Cycles, Leva, and Tyto. Plus: Akili Q3 results.
11.16.23
8 min. Read
metaMe Health seeks buyer by year-end. CMS offers up digital therapeutics nothingburger
11.06.23
6 min. Read
PDT Pipeline changes. Kinsa shuts down. Trials
10.27.23
5 min. Read
  • First
  • Previous
  • 1 of 20
  • Next
  • Last